| 研究課題/領域番号 |
20K20209
|
|---|
| 研究機関 | 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター) |
|---|
研究代表者 |
LI JUNJIE 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 研究員 (80869892)
|
|---|
| 研究期間 (年度) |
2020-04-01 – 2023-03-31
|
| キーワード | immunotherapy / nanoreactors / pyroptosis / self-assembly / vesicles / tumor metabolism |
|---|
| 研究実績の概要 |
We developed a oxidase-loaded nanoreactor that could specifically render tumor cells immunogenic by pyroptosis, a highly pro-inflammatory programmed cell death. Of particular interest, the vesicular system based on PICsomes is highly modular, generic, and simple and could be adapted to customize various kinds of activatable nanoreactors based on triggerable cross-linking membrane networks. As a consequence, the nanoreactor with self-boosting catalytic glucose oxidation could protect oxidase to initiate pyroptosis in the long term. We confirmed that not only glucose oxidase-loaded but also lactate oxidase-loaded nanoreactors could induce pyroptosis.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
1: 当初の計画以上に進展している
理由
1. We confirmed that the glucose and lactate could be simultaneously consumed by oxidase-loaded vesicular nanoreactor with accompanying ROS production, which aggravated nutrients metabolic stress to induce cancer cell death.
2. As a accident discovery, nanoreactors could induce an immunostimulatory form of cell death by pyroptosis, which has the great potential to prime anti-tumor immune responses.
|
| 今後の研究の推進方策 |
1. In vivo anti-tumor therapy is ongoing.
2. Combination therapy (nanoreactor plus anti-PD-1 immunotherapy) is also ongoing.
|
| 次年度使用額が生じた理由 |
Some reagents arrived later.
|
